Invicta Diagnostic IPO
| DATE | GMP (GREY MARKET PREMIUM) | EXPECTED LISTING GAINS |
|---|---|---|
| 03-Dec-2025 | 2 | 3200 |
| 02-Dec-2025 | 0 | 0 |
| 01-Dec-2025 | 0 | 0 |
| 30-Nov-2025 | 0 | 0 |
About the Company
Invicta Diagnostic IPO GMP is gaining attention in the diagnostics and healthcare segment due to its growing network of pathology and radiology centers. The company provides a wide range of diagnostic solutions, including blood tests, imaging services, and preventive health packages. With rising demand for affordable diagnostic services across India, the IPO aims to fund new lab setups, upgrade technology, and support working capital needs.
Investors are actively tracking the Invicta Diagnostic IPO GMP (Grey Market Premium) to analyse listing expectations. Early trends indicate positive sentiment, supported by the company’s strong customer base, operational efficiency, and expansion plans. Subscription levels from retail and NII categories are expected to influence final GMP movements.
The IPO is considered attractive due to the stable nature of the diagnostics industry, healthy revenue growth, and increasing market penetration. Investors looking for healthcare-focused IPOs are closely monitoring the subscription status and final allotment dates for better clarity. Overall, Invicta Diagnostic IPO is emerging as a notable offering in the SME IPO space with steady demand and decent listing expectations.
Invicta Diagnostic Ltd. IPO — Key Facts
• IPO Open Date: 1 December 2025
• IPO Close Date: 3 December 2025
• Basis of Allotment Date: 4 December 2025
• Refund Initiation / Credit to Demat Date: 5 December 2025
Listing Date (on NSE SME): 8 December 2025
🔹 Issue & Share Details
• Total Shares Offered / Fresh Issue: 33,08,800 equity shares.
• Total Issue Size: ₹28.12 crore (at upper price band), entirely a fresh issue — no Offer-For-Sale (OFS).
• Face Value per Share: ₹10
• Price Band: ₹80 to ₹85 per share.
• Lot Size (Minimum): 1,600 shares per lot.
• Retail Minimum Application: 2 lots = 3,200 shares → at upper price ₹85, investment ~ ₹2,72,000.
Investor Category Reservation (Offer)
Qualified Institutional Buyers (QIB): up to 50% of net issue
Non–Institutional Investors (NII / HNI): ≥ 15%
Retail Individual Investors: ≥ 35%
Invicta Diagnostic Ltd. is launching its SME-class IPO between 1 – 3 December 2025, offering 33,08,800 fresh equity shares at a price band of ₹80–85 per share, aggregating to ₹28.12 crore.
The IPO allotment is scheduled for 4 December 2025, with refund credit & share allocation around 5 December 2025, and listing on NSE SME targeted for 8 December 2025.
Retail investors need to apply for a minimum of 3,200 shares (i.e. two lots), which at ₹85/share means around ₹2,72,000.
The entire issue is a fresh capital raise — proceeds will support expansion plans, new diagnostic centres, and upgrading diagnostic equipment.
With clear timelines and transparent share-issue data, Invicta’s IPO is positioned as an accessible opportunity for both retail and institutional investors, especially in the growing diagnostics and healthcare services segment.